newsfilter
← Latest News
PR Newswire·

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

SAN DIEGO, March 6, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline,